Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Efficacy of Two Different Doses of Atorvastatin for Prevention of Periprocedural Ischemic Brain Damage in Chinese Patients Undergoing Carotid Artery Stenting (CAS)

X
Trial Profile

Efficacy of Two Different Doses of Atorvastatin for Prevention of Periprocedural Ischemic Brain Damage in Chinese Patients Undergoing Carotid Artery Stenting (CAS)

Status: Recruiting
Phase of Trial: Phase IV

Latest Information Update: 08 Apr 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Atorvastatin (Primary)
  • Indications Cardiovascular disorders; Cerebral ischaemia; Stroke
  • Focus Therapeutic Use
  • Acronyms PICAS
  • Most Recent Events

    • 08 Apr 2020 Planned End Date changed from 30 Oct 2019 to 30 Apr 2020.
    • 08 Apr 2020 Planned primary completion date changed from 30 Oct 2019 to 30 Apr 2020.
    • 28 Mar 2018 Planned End Date changed from 30 Dec 2018 to 30 Oct 2019.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top